Rigel Pharmaceuticals | RIGL - Pre Tax Profit


Rigel Pharmaceuticals reported $-1.03M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD -10.61M 263.52M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Veracyte USD 29.97M 10.66M Mar/2026